Lung epithelial cell damage and dysfunctional repair play a role in the development of lung disease. Effective repair likely requires the normal functioning of alveolar stem/progenitor cells. For example, we have shown in a mouse model of bronchopulmonary dysplasia (BPD) that mesenchymal stem cells (MSC) protect against hyperoxic lung injury at least in part by increasing the number of Epcam
+ Sca-1
+ distal lung epithelial cells. These cells are capable of differentiating into both small airway (CCSP
+) and alveolar (SPC
+) epithelial cells in three-dimensional (3D) organoid cultures. To further understand the interactions between MSC and distal lung epithelial cells, we added MSC to lung progenitor 3D cultures. MSC stimulated Epcam
+ Sca-1
+ derived organoid formation, increased alveolar differentiation and decreased self-renewal. MSC-conditioned media was sufficient to promote alveolar organoid formation, demonstrating that soluble factors secreted by MSC are likely responsible for the response. This work provides strong evidence of a direct effect of MSC-secreted factors on lung progenitor cell differentiation.

Lung diseases have large impacts on both pediatric and adult patients throughout the world. For example, the pathology in bronchopulmonary dysplasia (BPD) is characterized by depletion of or damage to the lung epithelial cells that normally facilitate gas exchange coupled with a disruption in vascular development1,2. A critical need for investigation of mechanisms of lung disease and novel therapeutics remains.

Repair in the distal lung is provided by a number of stem/progenitor populations, including Epcam
+ Sca-1
+ distal lung epithelial cells (a population enriched in lung progenitors formerly referred to as bronchioalveolar stem cells (BASCs)3), club (Clara) cells, AT2 cells, and alveolar progenitors. Lineage tracing studies and injury studies have shown club cells act as stem cells, producing club cells and ciliated cells4. AT2 cells and Integrin-alpha-6-expressing progenitors, also known as lineage-negative progenitors, produce AT2 cells and alveolar type 1 (AT1) cells5–8. Basal cells have been shown to be proximal airway progenitor cells in mice and are present in human distal airways9. Co-expression of the bronchiolar club cell marker, CCSP, and the AT2 cell marker, SPC (pro-surfactant protein C), in Epcam
+ Sca-1
+ distal lung epithelial cells (hereafter, Sca-1
+ cells) and their expansion seen after lung injury in vivo, suggested that these cells function in epithelial repair in the bronchiolar and alveolar compartments3,10. We and others have developed 3D co-culture systems to test the stem cell properties of lung epithelial cells when cultured with supporting stroma10–13. These systems permit alteration of lung stem cell type or stromal cell type to test effects on organoid growth, differentiation and self-renewal properties. These 3D co-culture approaches have revealed that Sca-1
+ cells produce lung cell organoids containing bronchiolar and alveolar cell types, providing evidence that they are multipotent lung stem cells10. While the direct relationships between lung stem cell potential in culture and in vivo remain to be determined, these and related findings suggest that many different distal lung cell types have the capacity to respond to lung injury14,15. Further, these data support the idea that lung injury repair in vivo is dependent on the specific type and location of injury, severity of damage, and the degree to which stroma that signal to epithelial cells are affected.

For progenitor cells to properly repair lung injury, such as damage to alveolar epithelial cells, it is necessary for a signal(s) to instruct the progenitor cell to produce alveolar progeny15,16. The precise signals from the

1Department of Pediatrics, Division of Newborn Medicine, Boston Children’s Hospital, Boston, MA, 02115, USA. 2Department of Pediatrics, Division of Hematology/Oncology, Stem Cell Program; Boston Children’s Hospital, Boston, MA, 02115, USA. 3Genetics Department, Harvard Medical School, Boston, MA, 02115, USA. 4Harvard Stem Cell Institute, Cambridge, MA, 02138, USA. 5Wellcome Trust/Medical Research Council Stem Cell Institute, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QR, UK. Correspondence and requests for materials should be addressed to K.T.L. (email: Kristen.leeman@childrens.harvard.edu) or C.F.K. (email: Carla.kim@childrens.harvard.edu)
Microenvironment that stimulate differentiation for repair of lung injury are unknown. Mesenchymal stem cell (MSC) delivery prevents lung injury in multiple animal models, including in the established neonatal hyperoxia mouse model of BPD14,17. MSC engraftment in these injury models is minimal and therapeutic benefit is likely triggered by a paracrine-mediated mechanism19. Both MSC and MSC-conditioned media (CM) treatment not only protected mice from injury, but also increased lung progenitors number in vivo14,17. Signals secreted from MSC likely activate lung epithelial progenitor cells to differentiate and repair injury. Microvesicles secreted from the MSC have been proposed to be the therapeutic factor present in MSC-CM for repair of lung injury20,21. It is possible that MSC-secreted factors replace missing microenvironmental signals that have been altered by injury to the lung supporting cells. This work uses a robust lung organoid system to show that critical signals secreted by the MSC trigger lung progenitor cells to differentiate and potentially play a critical role in enhancing repair of alveolar injury.

Results

Mesenchymal stem cells increase lung organoid formation. 3D co-culture experiments illustrated a direct effect of MSC on Sca-1+ cells by exhibiting a significantly increased organoid forming efficiency (Fig. 1). We have previously shown that in the mouse model of BPD, bone-marrow derived MSC (BMSC) treatment led to an increased number of Sca-1+ cells in vivo and in vitro using traditional 2-dimensional cultures41. Sca-1+ cells and Sca-1− cells (enriched for AT2 cells) were freshly isolated from 6–8 week old β−actin GFP mice or DsRed mice using established FACS signature (Sca-1+ distal lung progenitors: DAPI+, CD31+, CD45−, EP-CAM−, Sca-1−; AT2 cells: DAPI+, CD31+, CD45+, EP-CAM+, Sca-1−) (Fig. 1a, S1a). Sca-1+ and Sca-1− cells were co-cultured with either mouse derived MSC or lung mouse endothelial cells (MEC) in growth-factor reduced matrigel on an air liquid interface for 14 days (Fig. 1a). MEC were chosen as the comparison stromal population due to previous work establishing their role in lung progenitor cell differentiation16. The number of Sca-1+ organoids formed on day 14 was significantly increased by 1.7-fold when co-cultured with MSC compared to MEC. Specifically, the organoid forming efficiency (OFE) of Sca-1+/MEC co-cultures was 0.875, which was significantly decreased, compared to Sca-1+/MSC (1.5 OFE) co-cultures (p < 0.02) (Fig. 1b,c). Sca-1+ organoid formation was unaffected by stromal cell modulation between MSC and MEC; 3D cultures showed a nonsignificant difference in organoid forming efficiency with Sca-1+/MEC OFE 1.685 and Sca-1−/MEC OFE 1.76 (Fig. 1c). These experiments suggested that MSC selectively alter Sca-1− progenitors and do not affect other Sca-1+ lung progenitor cells such as AT2 cells. Furthermore, Sca-1−-derived organoids are larger when cultured with MSC compared to MEC (1.35-fold p < 0.05) (Fig. 1d), indicating that MSC enhance Sca-1+ cell proliferation and this is in agreement with previous in vivo results showing increased distal lung progenitor numbers in a neonatal murine model of BPD combined with mesenchymal stem cells treatment15. Sca-1− derived organoids showed no significant change in organoid size when co-cultured with MSC compared to MEC.

Mesenchymal stem cells stimulate alveolar differentiation of EpCam+Sca-1+ distal lung epithelial cells. To determine if MSC in Sca-1+ co-cultures influenced differentiation, we assessed the efficiency of lineage-specific organoid formation. Overall, Sca-1+ co-cultured with MSC produced a distinct differentiation pattern compared to Sca-1− cells co-cultured with MEC. After 14 days in co-culture, alveolar, bronchiolar, and bronchioalveolar (mixed) organoids were identified by morphology and by immunofluorescence staining for alveolar (SPC) and bronchiolar (CCSP) markers (Fig. 2a,b). Sca-1+/MSC co-cultures formed a significantly higher number of alveolar organoids compared to Sca-1−/MEC co-cultures (50.2% versus 34.8%; p = 0.005). Sca-1+/MEC co-cultures fostered the bronchioalveolar (mixed) organoid formation with a higher number of mixed organoids formed compared to Sca-1−/MSC co-cultures (34.7% versus 17.9%; p = 0.05). 778 organoids from Sca-1+ co-cultures were analyzed (298 organoids from Sca-1−/MEC co-culture and 480 organoids from Sca-1+/MSC co-culture). Sca-1+ cultures formed 100% alveolar organoids when cultured with either MEC or MSC. 171 organoids from Sca-1− co-cultures were analyzed (652 organoids from AT2/MEC co-culture and 519 organoids from AT2/MSC co-culture) (Fig. 2c). Confirming this result, qPCR analysis for SPC showed increased expression in Sca-1+ derived organoids when co-cultured with MSC compared to MEC (Fig. 2d). We also further characterized our alveolar organoids for evidence of alveolar type 1 (AT1) cells. Confirming that AT2 cells differentiate in our culture conditions, we detected cells that stained with antibodies for Aquaporin 5 and Podoplanin, two AT1 cell markers, in alveolar organoids. No significant difference was seen in the fraction of organoids containing AT1 cell markers when co-cultured with MEC versus MSC, supporting that MSC did not cause a change in AT2 to AT1 differentiation (Fig. S1b,c). These data show that lung progenitor differentiation can be altered by stromal signals in co-culture. Specifically, MSC stimulate Sca-1+ to form a higher number of differentiated alveolar organoids at the expense of bronchioalveolar organoids.

Mesenchymal stem cell combinations reduce Sca-1− distal lung epithelial cell self renewal ability. Next, serial passaging with different stromal cell/Sca-1− combinations was used to determine if MSC also impacted self-renewal functions. These experiments revealed that self-renewal was significantly decreased in Sca-1−/MSC cultures compared to Sca-1−/MEC cultures (Fig. 3a). Sca-1− cells serially passaged with MEC retained organoid forming efficiency ranging from 4.5−4.7%, while their serially passaged with MSC lost ability to form organoids in secondary and subsequent passages; secondary passage Sca-1−/MEC 4.5% versus Sca-1−/MSC 0.34%, p = 0.005; tertiary passage Sca-1−/MEC 4.7% versus Sca-1−/MSC 0.12%, p = 0.03; quaternary passage Sca-1−/MEC 4.5% versus 0.05%, p = 0.03. (Fig. 3a). MSC retained the ability to enhance Sca-1− organoid formation in secondary passage when the multi-potent state was initially fostered in primary passage with MEC, Sca-1−/MEC cultures had a significant 1.8x fold (p = 0.045) increased colony formation when co-cultured with MSC in secondary passage compared to MEC (Fig. 3b). No difference in secondary passaging ability with MEC versus MSC was observed for cells passaged from primary Sca-1−/MSC cultures. MEC co-culture did not restore the cells’ ability
Figure 1. Mesenchymal Stem Cells Increase Lung Organoid Formation in 3D Culture. (a) Schematic of FACS strategy and 3D organoid co-culture methods. Fresh lung cells were isolated from β-actin GFP mice and FACS strategy represents signature used to enrich for EpCam$^+$ Sca-1$^-$ cells and EpCam$^+$ Sca-1$^+$ cells. CD45$^+$ hematopoietic and CD31$^+$ endothelial cells were first excluded. EpCam$^+$ epithelial cells were selected and Sca-1$^+$ cells were enriched for lung progenitors and Sca-1$^-$ cells were enriched for AT2 cells. Isolated cells were placed in co-culture with either mouse lung endothelial cells (MEC) or mouse bone marrow derived mesenchymal stem cells (MSC) in growth factor reduced matrigel on an air-liquid interface 3D co-culture system. Representative images of the different stromal cells are shown in the lower panel. Scale bar: 50 μM. (b) Representative images of GFP$^+$ organoids formed from 3D co-culture of Sca-1$^+$ cells with MEC or MSC after 14 days in co-culture. Scale bar: 100 μM (c) Organoid forming efficiency (OFE) of Sca1$^+$/MEC co-cultures was 0.875 which was significantly decreased compared to Sca1$^+$/MSC (1.5 OFE) (p < 0.02). Quantification of number of GFP$^+$ lung organoids formed in co-culture after 14 days in culture showed a significant 1.7x increase in total Sca-1$^+$ colony number when co-cultured with MSC versus MEC. No significant difference in organoid forming efficiency is observed when Sca-1$^-$ cells are cultured with MEC or MSC, Sca-1$^-$/MEC OFE was 1.685 and Sca-1$^-$/MSC OFE was 1.76. (d) Organoid size measured on GFP$^+$ pictures from the indicated co-cultures show an increased colony size with Sca1$^+$/MSC co-cultures compared to Sca1$^+$/MEC co-cultures, p < 0.05. Data represented is the mean from 4 independent experiments with 3 wells per experimental state in each experiment. Error bars represent SD.
to form multipotent organoids in serial passage. This finding, together with the observed increase in alveolar organoid formation in Sca-1⁺/MSC co-cultures, supports the interpretation that MSC trigger irreversible lung progenitor differentiation and an associated decrease in self-renewal compared to the self-renewal stimulation seen with MEC.
Mesenchymal stem cell secreted factors stimulate lung organoid formation. Based on previous work suggesting MSC-secreted factors acting as therapeutic components, we tested the effect of MSC-conditioned media alone on lung stem cell functions in 3D culture. In these experiments, no stromal cell population was present indicating any change in stem cell properties was due to secreted factors alone. When Sca-1+ cells were cultured with conditioned media (CM) alone, more organoids formed using MSC-CM compared to MEC-CM (Fig. 4a). Culturing with MSC-CM concentrated 10×, Sca-1+ cells formed a 2.22 fold more organoids (p = 0.02) compared to controls with 10x MEC-CM. MSC-CM concentrated 5x showed a similar trend and yielded 1.33 fold more organoids compared to 5x MEC-CM, but did not reach statistical significance (Fig. 4a). No organoids were formed when 1x CM or 0.1x CM from either MSC or MEC or media alone was used (data not shown). A trend towards increased differentiation of Sca-1+/MSC-CM cultures to alveolar lineage compared to Sca-1+/MEC-CM cultures was observed (42.7% versus 23.7%; p > 0.05) and decreased bronchioalveolar/mixed organoids were
found in Sca-1⁺/MSC-CM cultures compared to Sca-1⁺/MEC-CM cultures (21.4% versus 37.6%; p > 0.05) but did not reach statistical significance (Fig. 4b). These experiments support that MSC secreted factors are responsible for the direct effect that MSCs impart on lung progenitors in organoid cultures.

A semi-quantitative membrane antibody array containing labels corresponding to 308 mouse proteins was used to identify candidate factors produced by MSC that may mediate the effects we observed on organoid formation. MSC were cultured in serum free media and supernatant was collected and was incubated with the membrane array (AAM-BLM-1, Ray-Biotech). Biotin-labeled MSC supernatant was incubated with the array overnight and hybridized with HRP-conjugated streptavidin and results were analyzed. TSP1, ICAM, MMP-9, and Epigen were identified on the antibody array and present in the MSC conditioned media (Fig. S2). We have previously shown that TSP1 stimulates alveolar differentiation of lung progenitor cells in organoid cultures and in vivo[10], making TSP1 a strong candidate factor in mediating the MSC effects we observed. Western blot analysis confirmed abundant TSP1 protein in MSCs (Fig. 4c). These experiments support the hypothesis that TSP1 and other MSC-secreted factors are responsible for the direct effect that MSCs impart on lung progenitors in organoid cultures.
Discussion

MSC-secreted factors have been hypothesized to be therapeutic activators of lung repair based on multiple animal models of lung injury and MSC treatments. MSC-secreted factors may prevent disease by replacing defective signals after injury and thereby triggering endogenous epithelial progenitor cells to repair injured epithelium. Determination of the active soluble factors secreted by MSC remains an active area of investigation and critical next step to understanding this direct effect. This work shows that MSC-secreted factors can act directly upon epithelial progenitor cells to alter their functions compared to MEC. Specifically, while MEC foster lung progenitor self renewal, MSC increase organoid formation and alveolar differentiation compared to controls. These alterations in lung progenitor function may be critical in the epithelial repair process.

This work reveals insights into the mechanisms of lung stem cell alveolar differentiation and provides opportunities for study of novel therapeutic opportunities to promote repair via stimulation of endogenous progenitor cells. We highlight the power of an in vitro system making it possible to study mechanisms underlying alterations in differentiation patterns. Together, these findings suggest defective supporting cell signaling to alveolar progenitors could occur in the setting of lung injury that can be rescued by MSC-secreted signals. Other organ systems have shown similar stimulation of stem cell functions by MSC. Bone marrow derived MSC have been shown to stimulate cardiac stem cell proliferation and differentiation. MSC-mediated paracrine signaling to endogenous progenitors may be responsible for enhanced repair at sites of injury in multiple organ systems. It is also possible that other non-soluble factors produced by MSC, such as extracellular matrix, may also contribute to epithelial progenitor response and our findings.

We have shown using lineage tracing studies that CCSP-expressing cells, including club cells and distal lung epithelial cells, repair bleomycin-induced alveolar injury. Others have also shown that CCSP-positive cells give rise to lineage-labeled alveolar cells, including AT2 and AT1 cells, after injury4,12. Yet, using the same lineage tracing mouse model, CCSP-expressing cells do not repair hyperoxia injury4 without any therapeutic factor administration. These contrasting results suggest that hyperoxia alters stem cell function, possibly due to altered supporting cell signaling, whereas bleomycin injury does not. MSC-secreted factors may replace the signals that hyperoxic injury impacts, triggering alveolar progenitor repair in the mouse model of BPD.

These studies show a direct effect of MSC-secreted factors on lung progenitor cell function. We previously defined a BMP4-NFATc1-TSP1 axis regulating adult lung epithelial progenitor cell differentiation and alveolar injury repair. Lung injury and lung endothelial cell damage may lead to altered BMP4-NFATc1-TSP1 signaling and defective triggering of alveolar progenitor function. MSC-secreted factors such as TSP1 may replace missing or aberrant vascular signals and activate epithelial repair. The presence of TSP1 in MSC supernatant, together with our previous findings, suggests TSP1 is one way that MSCs can affect alveolar differentiation. MSC-secreted TSP1 has also been shown to rescue neuron synaptic dysfunction in a mouse model of Alzheimer’s disease. Additional candidate MSC-secreted factors include ICAM, which is known to be induced during alveolarization and elevated after AT2 cell damage in rat injury models, MMP-9, which can be elevated and dysregulated in lung disease, and Epigen, which is altered in lung cancer suggesting a role in stem cell proliferation. Additional work is necessary to further examine the contribution of these candidate secreted components.

MSC-secreted factors may replace missing or aberrant signals and activate epithelial repair. The 3D lung organoid assays employed allow a unique opportunity to study mechanisms of direct signaling in alveolar progenitor populations. This assay could be used to test and identify therapeutic key soluble and non-soluble factors on candidate lung progenitor populations throughout the lung in response to specific lung injuries. There is significant translational relevance to these findings. Clinical trials are already underway using MSC in patients for which no real options exist for therapy or prevention. Recent phase 2a clinical trials have shown safety of bone marrow derived MSC intravenous delivery in moderate to severe acute respiratory distress syndrome (ARDS). MSC microvesicles have been shown to have therapeutic effects in an ex vivo perfused human lung model of severe bacterial pneumonia. At this stage, it is highly critical to understand the mechanisms of therapeutic action of these cells and their secreted products to ensure safety and efficacy. This work supports this mission as we begin to understand the mechanisms by which MSC stimulate progenitor cell activity and how these mechanisms may be utilized in the future to achieve therapeutic lung injury repair.

Methods

Mice. All mice work was approved by the Children Hospital Boston Animal Care and Use Committee, accredited by AAALAC, and was performed in accordance with relevant institutional and national guidelines and regulations. 8–10 week old transgenic β-actin-EGFP mice (C57BL/6) or β-actin-DsRed mice (B6.Cg-Tg(ACTB-DsRed-MST1Nagy/J)) were used for isolating lung epithelial cells. 2- to 4-week-old C57BL/6 were used to isolate endothelial cells.

Endothelial cell preparation. Lung MEC were isolated from 2- to 4-week-old mice by negative selection with anti-CD45-conjugated magnetic beads and positive selection with anti-CD31-conjugated magnetic beads. CD31-positive cells were then amplified in a gelatin-coated culture plate for 3–5 days followed by reselection with anti-CD31-conjugated magnetic beads. Endothelial cell purity was determined by IF staining for CD31, VE-Cadherin, and VEGFR2, and cells were used for experiments between passages 2 and 6. For Ac-LDL uptake, endothelial cells were incubated with 10 μg/ml Dil-ac-LDL for 2 hr at 37 °C followed by staining with DAPI. For matrigel tube formation, endothelial cells were seeded on matrigel-coated 24-well plates (1 × 10^6 cells/well), incubated for 1 hr at 37 °C, and added fresh medium. One to 3 days after plating, tube formation was confirmed.

MSC preparation. MSC were provided by the Hershenson laboratory. Bone marrow MSC were isolated and tested in the Prockop laboratory. MSC were isolated from femurs or lungs of mice (BALB/cBy, Jackson Labs, Bar Harbor, ME) and flow cytometry and differentiation analysis were performed and confirmed MSC properties.

\[ \text{MSC-secreted factors may replace missing or aberrant signals and activate epithelial repair.} \]

\[ \text{The 3D lung organoid assays employed allow a unique opportunity to study mechanisms of direct signaling in alveolar progenitor populations. This assay could be used to test and identify therapeutic key soluble and non-soluble factors on candidate lung progenitor populations throughout the lung in response to specific lung injuries.} \]

\[ \text{There is significant translational relevance to these findings. Clinical trials are already underway using MSC in patients for which no real options exist for therapy or prevention. Recent phase 2a clinical trials have shown safety of bone marrow derived MSC intravenous delivery in moderate to severe acute respiratory distress syndrome (ARDS).} \]

\[ \text{MSC microvesicles have been shown to have therapeutic effects in an ex vivo perfused human lung model of severe bacterial pneumonia. At this stage, it is highly critical to understand the mechanisms of therapeutic action of these cells and their secreted products to ensure safety and efficacy. This work supports this mission as we begin to understand the mechanisms by which MSC stimulate progenitor cell activity and how these mechanisms may be utilized in the future to achieve therapeutic lung injury repair.} \]
For bone-marrow derived MSC, as described by Peister31, cells were isolated from femurs, plated, and expanded per protocol previously described. Differentiation assays for osteogenesis, adipogenesis, and chondrocyte differentiation were performed32.

**Epithelial cell isolation and 3D organoid assay.** Primary lung epithelial cells were isolated from 8–10 week old β-actin-EGFP mice or β-actin-dsRed mice, as previously described30 using pan CD45-APC, CD31-APC, Sca-1 (Ly-6A/E)-APC-Cy7 (PharMingen), EpCAM-PE-Cy7 (BioLegend) with 4′, 6-diamidino-2-phenylindole (DAPI) (Sigma) staining to eliminate dead cells. Cell sorting was performed with a BD FACS Aria and data were analyzed with FlowJo software (Tree Star, Inc.). Amplified MEC or MSC were used for 3D co-cultures of Epacam^+ Sca-1^- cells and Epacam^- Sca-1^+ cells or dissociated organoids from the latter. MEC or MSC were added to growth factor–reduced Matrigel (BD Bioscience) at 1 × 10^6 cells/ml. Sorted Epacam^- Sca-1^- and Epacam^+ Sca-1^- cells were resuspended in the MEC or MSC containing Matrigel, which was pre-diluted at a ratio of 1:1 with medium and added to a 24-well transwell filter inserts with 0.4um pore (Corning) in a 24-well tissue culture plate containing 500µl of medium. Dulbecco’s Modified Eagle’s Medium/F12 (Invitrogen) was supplemented with 10% FBS, penicillin/streptomycin, 1 mM HEPES, and insulin/transferrin/selenium (Sigma) for all cultures. Cultures were incubated at 37 °C in a humidified incubator (5% CO2), and the medium was replaced every other day for up to 14 days. For serial passages, Epacam^- Sca-1^- and Epacam^+ Sca-1^- cells 3D cocultures were dissociated in dispase (BD Bioscience) and trypsin (GIBCO) to generate a single-cell suspension followed by FACs for GFP (or DsRED), GFP^+ (or DsRED^+) cells were resuspended with fresh MEC or MSC/Matrigel mixtures. Typically, 2,000 cells were plated for primary organoid (1°) formation. Primary organoids were dissociated, FACS sorted for GFP (or DsRED), and 2,500 GFP^- (or DsRED^-) cells were replated with fresh MEC or MSC/Matrigel mixture for secondary (2°) and subsequent (3° and 4°) organoid formation biweekly.

**Conditioned media preparation.** MEC and MSC confluent cultures were incubated in serum-free α-MEM media for 24 hours, and conditioned media representing equal number of cells were concentrated 10-fold or 5-fold using Amicon Ultra Centrifugal Filter Device (Millipore, Billerica, MA) with a molecular weight cutoff of 10 kDa as per manufacturer’s recommendations. 1x, 0.1x conditioned media and non-conditioned medium were added to a 24-well transwell filter inserts with 0.4um pore (Corning) in a 24-well tissue culture plate containing 500µl of medium. Dulbecco’s Modified Eagle’s Medium/F12 (Invitrogen) was supplemented with 10% FBS, penicillin/streptomycin, 1 mM HEPES, and insulin/transferrin/selenium (Sigma) for all cultures. Cultures were incubated at 37 °C in a humidified incubator (5% CO2), and the medium was replaced every other day for up to 14 days. For serial passages, Epacam^- Sca-1^- and Epacam^+ Sca-1^- cells 3D cocultures were dissociated in dispase (BD Bioscience) and trypsin (GIBCO) to generate a single-cell suspension followed by FACs for GFP (or DsRED), GFP^+ (or DsRED^+) cells were resuspended with fresh MEC or MSC/Matrigel mixtures. Typically, 2,000 cells were plated for primary organoid (1°) formation. Primary organoids were dissociated, FACS sorted for GFP (or DsRED), and 2,500 GFP^- (or DsRED^-) cells were replated with fresh MEC or MSC/Matrigel mixture for secondary (2°) and subsequent (3° and 4°) organoid formation biweekly.

**RNA isolation, reverse transcription and quantitative real-time PCR.** Total RNA was isolated from 3D culture wells using Absolutely RNA Nanoprep Kit (Agilent). cDNA was synthesized from total RNA using the Superscript III RT (Invitrogen). PCRs were performed using a Taqman Gene Expression Master Mix (Invitrogen) with specific taqman probes for Gapdh (Invitrogen 4352339E) and Sftpc (Invitrogen Mm00488144_m1).

**Histology and immunofluorescence.** Paraffin sections were stained with hematoxylin/eosin (H&E) or immunostained. For immunofluorescence, after deparaffinization and antigen retrieval process, sections were incubated with primary antibodies according to manufacturer’s instructions after blocking for 1h at room temperature. The slides were then washed and incubated with the appropriate secondary antibodies and labeling dyes. Secondary antibodies were coupled to Alexa-488, or Alexa-568 fluorochromes. After washing, tissue sections were mounted with Prolong gold with DAPI. Primary antibodies used are the following: SPC (Abcam ab211326), CCSP (Santa Cruz sc-390313), Podoplanin (Abcam ab11936) and Aquaporin 5 (Abcam ab11936). The mouse-specific biotin label-based antibody array (RayBio® Biotin Label-based Mouse Antibody Array I, L-Series, RayBiotech, Norcross, USA) that detects 308 different mouse target proteins was performed using MSC conditioned media. Two hundred µg of supernatant protein were biotin- labeled according to manufacturer’s instructions. Biotin-labeled supernatant were incubated with the array overnight at 4 °C followed by hybridization with HRP-conjugated streptavidin. Mouse antibody arrays were developed using Pierce ECL2 kit (Pierce, Thermo scientific) and quantified with Typhoon 9410 scanner-ImageQuantTL 7.0 software (GE Healthcare Europe, Barcelona, Spain). The analysis was performed with RayBio® Antibody Array Analysis Tool using a normalization according to positive control densities after background subtraction.

**Antibody array and western blotting analysis.** The mouse-specific biotin label-based antibody array (RayBio® Biotin Label-based Mouse Antibody Array I, L-Series, RayBiotech, Norcross, USA) that detects 308 different mouse target proteins was performed using MSC conditioned media. Two hundred µg of supernatant protein were biotin- labeled according to manufacturer’s instructions. Biotin-labeled supernatant were incubated with the array overnight at 4 °C followed by hybridization with HRP-conjugated streptavidin. Mouse antibody arrays were developed using Pierce ECL2 kit (Pierce, Thermo scientific) and quantified with Typhoon 9410 scanner-ImageQuantTL 7.0 software (GE Healthcare Europe, Barcelona, Spain). The analysis was performed with RayBio® Antibody Array Analysis Tool using a normalization according to positive control densities after background subtraction.

Digital images were acquired using: 1) Nikon/eclipse TE2000-S equipped with a digital Sight DS2mvdw camera and 2) Nikon/eclipse 90i equipped with a Nikon DSF11 camera. Acquisition was performed using NIS software. Images were composed and analyzed with Fiji software. To assess organoid size, individual colonies were manually outlined and their area was determined with Fiji software. 

**Statistical analysis.** All experiments were carried out at least three times independently. Graph-Pad Prism (GraphPad Software, La Jolla, CA, USA) and Mstat (Mstat Software, McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, WI, USA) were used for graphing and statistical analyses. Kruskal-Wallis test (independent samples, two-sided) was used for pairwise comparisons among groups at each condition. More than two groups of data were analyzed by one-way ANOVA with non-parametic Kruskal-Wallis test. In the figures, ***P ≤ 0.001, **P ≤ 0.01, and *P ≤ 0.05.

**Data Availability** All data generated or analyzed during this study are included in this published article (and its Supplementary Information files) or available from the corresponding author on reasonable request.
References

1. Rock, J. R. et al. Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. Proc Natl Acad Sci USA 108, E1475–1483, https://doi.org/10.1073/pnas.1117988108 (2011).

2. McEvoy, C. T. et al. Bronchopulmonary dysplasia: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. Ann Am Thorac Soc 11(Suppl 3), S146–153, https://doi.org/10.1513/AnnalsATS.201312-424LD (2014).

3. Kim, C. F. et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121, 823–835, https://doi.org/10.1016/j.cell.2005.03.032 (2005).

4. Rawlins, E. L. et al. The role of Scgb1a1+ Clara cells in the long-term maintenance and repair of lung airway, but not alveolar, epithelium. Cell Stem Cell 4, 525–534, https://doi.org/10.1016/j.stem.2009.04.002 (2009).

5. Barkauskas, C. E. et al. Type 2 alveolar stem cells are stem cells in adult lung. J Clin Invest 123, 3025–3036, https://doi.org/10.1172/JCI8782 (2013).

6. Chapman, H. A. et al. Integrin alphabeta6 identifies an adult distal lung epithelial population with regenerative potential in mice. J Clin Invest 121, 2855–2862, https://doi.org/10.1172/JCI57673 (2011).

7. Desai, T. J., Brownfield, D. G. & Krasnow, M. A. Alveolar progenitor and stem cells in lung development, renewal and cancer. Nature 507, 190–194, https://doi.org/10.1038/nature12930 (2014).

8. Vaughan, A. E. et al. Lineage-negative progenitors mobilize to regenerate lung epithelium after major injury. Nature 517, 621–625, https://doi.org/10.1038/nature14112 (2015).

9. Rock, J. R. et al. Basal cells as stem cells of the mouse trachea and human airway epithelium. Proc Natl Acad Sci USA 106, 12771–12775, https://doi.org/10.1073/pnas.0906850106 (2009).

10. Lee, J. H. et al. Lung stem cell differentiation in mice directed by endothelial cells via a BMP4-NFATc1-thrombospondin-1 axis. Cell 156, 440–455, https://doi.org/10.1016/j.cell.2013.12.039 (2014).

11. Lee, J. H. et al. Surfactant protein-C chromatin-bound green fluorescence protein reporter mice reveal heterogeneity of surfactant protein C-expressing lung cells. Am J Respir Cell Mol Biol 48, 288–298, https://doi.org/10.1165/rcmb.2011-0403OC (2013).

12. McQuilter, J. L., Yuen, K., Williams, B. & Bertoncello, I. Evidence of an epithelial stem/progenitor cell hierarchy in the adult mouse lung. Proc Natl Acad Sci USA 107, 1414–1419, https://doi.org/10.1073/pnas.0909270107 (2010).

13. Teisanu, R. M. et al. Functional analysis of two distinct bronchiolar progenitors during lung injury and repair. Am J Respir Cell Mol Biol 44, 794–803, https://doi.org/10.1165/rcmb.2010-0989OC (2011).

14. Tropea, K. A. et al. Bronchioalveolar stem cells increase after mesenchymal stromal cell treatment in a mouse model of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 302, L829–837, https://doi.org/10.1152/ajplung.00347.2011 (2012).

15. Donne, M. L., Lechner, A. J & Rock, J. R. Evidence for lung epithelial stem cell niches. BMC Dev Biol 15, 32, https://doi.org/10.1186/s12861-015-0082-9 (2015).

16. Zepp, J. A. et al. Distinct Mesenchymal Lineages and Niches Promote Epithelial Self-Renewal and Myofibrogenesis in the Lung. Cell 170, 1134–1148 e1110, https://doi.org/10.1016/j.cell.2017.07.034 (2017).

17. Aslam, M. et al. Bone marrow stromal cells attenuate lung injury in a murine model of neonatal chronic lung disease. Am J Respir Crit Care Med 180, 1122–1130, https://doi.org/10.1164/rccm.200902-0242OC (2009).

18. van Haften, T. et al. Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats. Am J Respir Crit Care Med 180, 1131–1142, https://doi.org/10.1164/rccm.200902-0179OC (2009).

19. Lee, J. W., Fang, X., Krasnodembskaya, A., Howard, J. P. & Matthay, M. A. Concise review: Mesenchymal stem cells for acute lung injury: role of paracrine soluble factors. Stem Cells 29, 913–919, https://doi.org/10.1002/stem.643 (2011).

20. Monsel, A., Zhu, Y. G., Gadapatu, V., Lim, H. & Lee, J. W. Mesenchymal stem cell derived secreteome and extracellular vesicles for acute lung injury and other inflammatory lung diseases. Expert Open Biol Ther 16, 859–871, https://doi.org/10.1517/14712598.2016.1170804 (2016).

21. Schematic, K. & Kourembanas, S. MSC microvesicles for the treatment of lung disease: a new paradigm for cell-free therapy. Antioxid Redox Signal 21, 1905–1915, https://doi.org/10.1089/ars.2013.5784 (2014).

22. Hatzistergos, K. E. et al. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res 107, 913–922, https://doi.org/10.1161/CIRCRESAHA.110.222703 (2010).

23. Kim, D. H. et al. Thrombospondin-1 secreted by human umbilical cord blood-derived mesenchymal stem cells rescues neurons from synaptic dysfunction in Alzheimer’s disease model. Sci Rep. 8(1), 354 (10 Jan 2018).

24. Attar, M. A. et al. Induction of ICAM-1 expression on alveolar epithelial cells during lung development in rats and humans. Exp Lung Res 25, 245–259 (1999).

25. Buckley, S. et al. The milieu of damaged alveolar epithelial type 2 cells stimulates alveolar wound repair by endogenous and exogenous progenitors. Am J Respir Crit Care Med 185, 4512–4521, https://doi.org/10.1164/rccm.201503-0375OC (2015).

26. Kong, M. Y., Liao, W., Groves, P. C. & Matthay, M. A. Pulmonary matrix metalloproteinase-9 activity in mechanically ventilated children with respiratory syncytial virus. Eur Respir J 43, 1086–1096, https://doi.org/10.1183/09031936.0015613 (2014).

27. Taniguchi, K. et al. Epigen is induced during the interleukin-13-stimulated cell proliferation in murine primary airway epithelial cells. Exp Lung Res 37, 461–470, https://doi.org/10.3109/01902148.2011.596894 (2011).

28. Matthay, M. A. et al. Treatment with allodigenic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir Med. https://doi.org/10.1016/S2213-2600(18)30418-1 (2018).

29. Vintersten, K. et al. Mouse in red: red fluorescent protein expression in mouse ES cells, embryos, and adult animals. Genesis 40, 241–246, https://doi.org/10.1002/gene.20095 (2004).

30. Matsumoto, J. K. et al. Ovalbumin sensitization and challenge increases the number of lung cells possessing a mesenchymal stromal cell phenotype. Respir Res 11, 127, https://doi.org/10.1186/1465-9921-11-127 (2010).

Acknowledgements

The authors would like to thank the Marc Hershenson laboratory for sharing bone marrow derived MSCs. This work was supported by grants from the National Institutes of Health (NIH) to K.T.L. (5K12HD052896-09), (5T32HD007466-14), Hope Funds for Cancer Research (J.H.L.), RO1 HL090136 (C.E.K.), R01 HL125821 (C.E.K.), R01 HL132266 (C.E.K.), U01 HL100402 RFA-HL-09-004 (C.E.K.), a Basil O’Conner March of Dimes Starter Award (C.E.K.), and the Harvard Stem Cell Institute Support (C.E.K.); support from the Pulmonary Fibrosis Foundation to K.T.L. (J M Rosenzweig Young Investigator Award) and Boston Children’s Hospital Office of Faculty Development to K.T.L. (Career Development Award).
Author Contributions
K.T.L., J.H.L. and C.F.K. conception and design of research, edited and revised manuscript. K.T.L., P.P. and J.H.L. performed experiments. K.T.L. and C.F.K. analyzed data, interpreted results of experiments, K.T.L. and P.P. prepared figures and drafted manuscript. K.T.L. and C.F.K. approved final version of manuscript.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-42819-1.

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019